NMN and NR Label Updates 2020-2026: FDA Status, Safety, and What the Regulation Actually Says

Why NMN and NR Have No FDA Drug Label

Neither nicotinamide mononucleotide (NMN) nor nicotinamide riboside (NR) has received FDA approval as a pharmaceutical drug. No New Drug Application (NDA) or Biologics License Application (BLA) has been submitted or approved for either molecule, meaning no FDA-regulated prescribing information, black box warnings, or structured product labels exist for these NAD+ precursors as of May 2026.

The regulatory story here is unusual. Both compounds were widely sold as dietary supplements before any drug developer filed an Investigational New Drug (IND) application. That IND filing is what triggered the regulatory chain reaction that split the fates of NMN and NR into two very different paths. NMN was pulled from supplement shelves. NR stayed.

The distinction rests on a provision in the Federal Food, Drug, and Cosmetic Act, specifically section 201(ff)(3)(B), which excludes from the definition of "dietary supplement" any article that was first authorized for investigation as a new drug before it was marketed as a food or supplement 1. This is not a safety judgment. It is a procedural classification, and it has had enormous commercial consequences for the NAD+ precursor market.

Understanding this split requires walking through the regulatory timeline year by year.

2020-2021: NMN and NR Both Sold Freely as Supplements

Through 2020 and into 2021, both NMN and NR were available over the counter across the United States. Dozens of brands sold NMN capsules at doses ranging from 125 mg to 500 mg per serving. ChromaDex marketed NR under the brand name Tru Niagen, backed by a self-affirmed Generally Recognized as Safe (GRAS) determination and a New Dietary Ingredient (NDI) notification accepted by FDA 2.

During this window, the most significant clinical publication was the Yoshino et al. trial in Science (2021). This study enrolled 25 postmenopausal women with prediabetes and gave them 250 mg/day of NMN for 10 weeks. The primary finding: NMN increased skeletal muscle insulin signaling, measured by phosphorylation of AKT and mTOR, by approximately 30% compared to placebo 3. The trial did not find significant changes in body weight, blood pressure, or plasma lipids. It was small. But it was the first rigorous, placebo-controlled human study to show a metabolic effect for NMN.

Dr. Samuel Klein, senior author on the Yoshino study and professor at Washington University School of Medicine, stated: "These results provide the first evidence that NMN has a direct effect on metabolic function in humans, specifically on skeletal muscle, a major site of insulin resistance."

No label changes occurred during this period because there was no label to change.

The 2022 FDA Determination: NMN Loses Supplement Status

The key regulatory event occurred in October and November 2022. FDA responded to two citizen petitions (from NNB Nutrition and Natural Health Research Institute) asking the agency to confirm that NMN could be lawfully marketed as a dietary supplement 4.

FDA's answer was no.

The agency determined that NMN had been "authorized for investigation as a new drug" before it was marketed as a dietary supplement, based on the existence of an active IND held by Metro International Biotech (MIB) for their compound MIB-626 (a crystalline form of NMN). Under section 201(ff)(3)(B) of the FD&C Act, this excluded NMN from the dietary supplement definition.

The critical legal question was timing. FDA concluded that substantial clinical investigations of NMN as a drug had been "authorized" and made public before NMN was marketed as a food or dietary supplement. MIB's IND preceded the widespread supplement sales.

This determination did not declare NMN unsafe. It did not evaluate NMN's efficacy. The decision was procedural, not pharmacological. Yet its commercial impact was immediate: major retailers including Amazon removed NMN products from their platforms within weeks of the announcement.

NR's Separate Regulatory Path

NR was not affected by the 2022 determination. This is a point many consumers misunderstand.

ChromaDex had filed its NDI notification for NR (as Niagen) in 2015, and FDA did not object. The company also obtained self-affirmed GRAS status for NR chloride, supported by toxicology studies showing no adverse effects at doses up to 300 mg/kg/day in rats 5. No IND for NR as a standalone drug preceded its supplement marketing in a way that triggered the exclusion clause.

The Martens et al. (2018) crossover trial provided key human safety data for NR. This study gave 24 lean, healthy older adults (ages 55 to 79) 500 mg NR twice daily (1,000 mg/day total) for 6 weeks. NR raised whole-blood NAD+ by approximately 60% and was "well tolerated with no serious adverse events" 6. Blood pressure showed a trend toward reduction (systolic BP decreased by a mean of 5 mmHg), though the trial was not powered to detect cardiovascular endpoints.

A dedicated safety pharmacokinetics study by Conze et al. (2019) further confirmed NR tolerability at 100, 300, and 1,000 mg/day for 8 weeks in 140 overweight adults, with adverse event rates comparable to placebo across all dose groups 7. No clinically significant changes in liver function tests, renal biomarkers, or hematology were observed.

As of May 2026, NR products continue to carry standard dietary supplement labeling under 21 CFR 101.36 (Supplement Facts panel), not a drug facts label or FDA-approved prescribing information.

What Supplement Labels for NR Can and Cannot Claim

Because NR remains classified as a dietary supplement, its labeling follows DSHEA (Dietary Supplement Health and Education Act) rules, not drug labeling regulations 8.

Permitted claims include structure/function statements such as "supports cellular NAD+ production" or "promotes healthy aging at the cellular level." These require a truthful and non-misleading basis, a disclaimer stating "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease," and notification to FDA within 30 days of first use.

NR labels cannot claim to treat insulin resistance, prevent neurodegeneration, extend lifespan, or reduce the risk of any specific disease. Any such claim would render the product an unapproved new drug under federal law.

ChromaDex's Tru Niagen label lists nicotinamide riboside chloride as the active ingredient, typically at 300 mg per capsule. The Supplement Facts panel also lists microcrystalline cellulose, hypromellose (capsule shell), and vegetable stearate. No prescription-style sections (boxed warnings, clinical pharmacology, drug interactions) appear because the product is not regulated as a drug.

The FDA's Dr. Cara Welch, then-Director of the Office of Dietary Supplement Programs, commented in 2022: "The determination regarding NMN is specific to that ingredient and its regulatory history. It does not change the status of other NAD+ precursors that were lawfully marketed before any drug investigation began."

Clinical Evidence Accumulating Without a Drug Label

The absence of an FDA drug label has not stopped clinical research. Between 2020 and 2026, dozens of human trials explored both NMN and NR across metabolic, cardiovascular, and aging-related endpoints 9.

For NMN, the evidence base after Yoshino et al. includes:

A 2022 randomized controlled trial (Yi et al.) in 66 healthy middle-aged adults found that 12 weeks of NMN at 600 mg or 900 mg/day raised blood NAD+ levels by 38% to 51% compared to baseline and improved 6-minute walk distance 10. No serious adverse events occurred. Liver and kidney function remained normal across all groups.

MIB-626, the pharmaceutical-grade NMN under IND, completed Phase I safety studies and moved into Phase II trials for metabolic and age-related conditions. Published Phase I data showed dose-proportional increases in plasma NAD+ metabolites at single doses of 1,000 mg and 2,000 mg, with a half-life of roughly 2.5 hours for circulating NMN 11.

For NR, the CHROME-EXT extension study followed participants taking 300 mg/day for up to 12 months and reported sustained NAD+ elevation with no new safety signals. Elhassan et al. (2019) demonstrated in 12 older men that NR at 1,000 mg/day for 21 days increased skeletal muscle NAD+ by 2.3-fold and reduced circulating inflammatory cytokines including IL-6 and IL-2 12.

None of these trials has generated an FDA-approved drug label. The data sit in the published literature, available for prescribers to reference off-label but not summarized in any official Prescribing Information document.

Safety Signals and Adverse Event Monitoring

Without a drug label, there is no FDA-mandated post-marketing surveillance system for NMN or NR. Adverse events related to dietary supplements can be reported through the FDA's CFSAN Adverse Event Reporting System (CAERS), but reporting is voluntary for consumers and mandatory only for supplement manufacturers who receive serious adverse event reports 13.

Published safety data across all human NMN and NR trials (combined N > 500 participants) show a consistent pattern: mild gastrointestinal complaints (nausea, bloating, diarrhea) at rates of 5% to 12%, generally resolving within the first week of dosing. No hepatotoxicity, nephrotoxicity, or serious cardiovascular events have been attributed to either compound in controlled trials 7.

One theoretical concern involves cancer biology. NAD+ is required for DNA repair, but it is also consumed by cancer cells for proliferation. Preclinical data in mouse models have yielded mixed results: some studies show NMN reducing tumor burden, while others suggest high-dose NAD+ repletion could fuel existing malignancies 14. No human trial has reported increased cancer incidence, but trial durations (typically 4 to 12 weeks) are too short to assess long-term oncologic risk.

This gap in long-term human safety data is precisely the kind of information that a drug approval process and resulting label would address. A Phase III program for MIB-626 or any NMN drug product would require 6- to 12-month safety datasets before NDA submission.

International Regulatory Status

Japan classified NMN as a food ingredient in 2020, allowing it to be sold in foods and supplements without pre-market approval. Several Japanese clinical trials have proceeded under this framework, including studies at Keio University examining NMN's effect on sleep quality and physical endurance.

The European Union has not approved NMN as a novel food. Under EU Regulation 2015/2283, any food or food ingredient without a significant history of consumption in the EU before May 1997 requires a novel food authorization. As of May 2026, no NMN novel food application has been approved by the European Food Safety Authority (EFSA) 15.

NR's regulatory position in the EU is slightly different. ChromaDex submitted a novel food application for NR chloride, and EFSA issued a positive safety opinion for doses up to 300 mg/day in adults. Several EU member states allow NR supplement sales under this authorization.

Australia's Therapeutic Goods Administration (TGA) lists NR as a permitted ingredient in listed medicines (the Australian equivalent of dietary supplements) but has not evaluated NMN for inclusion on the Australian Register of Therapeutic Goods.

What to Expect: The MIB-626 IND and Potential Label Creation

The only pathway that could produce an FDA-approved drug label for NMN is completion of the MIB-626 clinical development program. Metro International Biotech's Phase II trials are evaluating MIB-626 for age-related metabolic decline, with endpoints including insulin sensitivity, body composition, and physical performance 11.

If MIB-626 reaches NDA submission and approval, the resulting prescribing information would contain the standard FDA label sections: indications and usage, dosage and administration, contraindications, warnings and precautions, adverse reactions, drug interactions, and use in specific populations.

Until that happens, clinicians prescribing NMN or NR do so without any FDA-sanctioned reference document. Compounding pharmacies in some states prepare NMN as a compounded product under state pharmacy board oversight, which introduces a separate set of labeling requirements under USP 795/797 compounding standards. These labels list the active ingredient, concentration, beyond-use date, and storage conditions but carry no FDA-reviewed clinical information.

For patients currently taking NR as a supplement, the label they receive reflects DSHEA requirements only. For those obtaining NMN from compounders or international sources, labeling varies widely in quality and accuracy. Clinicians should verify third-party testing (USP, NSF, or ConsumerLab certification) for any NAD+ precursor product recommended to patients.

A fasting blood NAD+ level can be measured through specialty laboratories to confirm whether supplementation is raising NAD+ as expected, with a target increase of 40% to 60% above baseline within 2 to 4 weeks at standard dosing 6.